2023
The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence
Ragnhildstveit A, Roscoe J, Bass L, Averill C, Abdallah C, Averill L. The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence. Therapeutic Advances In Psychopharmacology 2023, 13: 20451253231154125. PMID: 36895431, PMCID: PMC9989422, DOI: 10.1177/20451253231154125.Peer-Reviewed Original ResearchPosttraumatic stress disorderClinical evidenceStress disorderMethyl-d-aspartate (NMDA) receptor antagonistLow patient engagementRobust antidepressant effectsOpen-label studyOnset of actionPotential of ketamineQuality of lifeMedical comorbiditiesAntidepressant effectsChart reviewRefractory casesDisease chronicityClinical presentationRandomized trialsCase reportDevastating conditionReceptor antagonistMajor depressionPharmacological approachesPsychiatric disordersPharmacological agentsTherapeutic safety
2022
Abnormal glutamate metabolism in prefrontal cortex of post-traumatic stress disorder linked to comorbidity with major depression
Swanberg K, Prinsen H, Averill C, Campos L, Kurada A, Krystal J, Petrakis I, Averill L, Abdallah C, Juchem C. Abnormal glutamate metabolism in prefrontal cortex of post-traumatic stress disorder linked to comorbidity with major depression. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2022 DOI: 10.58530/2022/3344.Peer-Reviewed Original Research